Abstract
The intent of this article is to summarize current body of knowledge on the potential implication of the xanthine oxidase pathway (XO) on skeletal muscle damage. The possible involvement of the XO pathway in muscle damage is exemplified by the role of XO inhibitors (e.g., allopurinol) in attenuating muscle damage. Reliance on this pathway (as well as on the purine nucleotide cycle) could be exacerbated in conditions of low muscle glycogen availability. Thus, we also summarize current hypotheses on the etiology of both baseline and exertional muscle damage in McArdle disease, a condition caused by inherited deficiency of myophosphorylase. Because myophosphorylase catalyzes the first step of muscle glycogen breakdown, patients are unable to obtain energy from their muscle glycogen stores. Finally, we provide preliminary data from our laboratory on the potential implication of the XO pathway in the muscle damage that is commonly experienced by these patients.
Keywords: McArdle disease, xanthine oxidase, muscle damage, rhabdomyolysis, oxidative stress.
Current Pharmaceutical Design
Title:Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease
Volume: 22 Issue: 18
Author(s): Helios Pareja-Galeano, Alejandro Santos-Lozano, María Morán, Fabian Sanchis-Gomar, Rafael Alis, Alfredo Santalla, Alejandro F. San Juan, Jorge Díez-Bermejo, Miguel A. Martín, Joaquín Arenas and Alejandro Lucia
Affiliation:
Keywords: McArdle disease, xanthine oxidase, muscle damage, rhabdomyolysis, oxidative stress.
Abstract: The intent of this article is to summarize current body of knowledge on the potential implication of the xanthine oxidase pathway (XO) on skeletal muscle damage. The possible involvement of the XO pathway in muscle damage is exemplified by the role of XO inhibitors (e.g., allopurinol) in attenuating muscle damage. Reliance on this pathway (as well as on the purine nucleotide cycle) could be exacerbated in conditions of low muscle glycogen availability. Thus, we also summarize current hypotheses on the etiology of both baseline and exertional muscle damage in McArdle disease, a condition caused by inherited deficiency of myophosphorylase. Because myophosphorylase catalyzes the first step of muscle glycogen breakdown, patients are unable to obtain energy from their muscle glycogen stores. Finally, we provide preliminary data from our laboratory on the potential implication of the XO pathway in the muscle damage that is commonly experienced by these patients.
Export Options
About this article
Cite this article as:
Pareja-Galeano Helios, Santos-Lozano Alejandro, Morán María, Sanchis-Gomar Fabian, Alis Rafael, Santalla Alfredo, F. San Juan Alejandro, Díez-Bermejo Jorge, A. Martín Miguel, Arenas Joaquín and Lucia Alejandro, Xanthine Oxidase Pathway and Muscle Damage. Insights from McArdle Disease, Current Pharmaceutical Design 2016; 22 (18) . https://dx.doi.org/10.2174/1381612822666160210144419
DOI https://dx.doi.org/10.2174/1381612822666160210144419 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Thromboxane A2 Receptor Blockade Prevents Atherosclerotic Process by its Anti-Inflammatory Effect
Vascular Disease Prevention (Discontinued) New Frontiers in the Management of Acute Coronary Syndromes: Cangrelor and Elinogrel
Recent Patents on Cardiovascular Drug Discovery Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume II)
CNS & Neurological Disorders - Drug Targets An Update on the Cardiovascular Effects of Quercetin, a Plant Flavonoid
Current Nutrition & Food Science Aldose Reductase, Oxidative Stress and Diabetic Cardiovascular Complications
Cardiovascular & Hematological Agents in Medicinal Chemistry HCV-Related Transformation and New Therapeutic Strategies: An Update
Current Cancer Therapy Reviews Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Oxidative Brain Damage by Peroxynitrite in Bacterial Meningitis: A Target for Adjunctive Therapy?
Current Medicinal Chemistry - Central Nervous System Agents Inhibitory Effects of Flavonolignans from Silybum marianum (L.) Gaertn (Milk Thistle) on Function of Aldehyde Oxidase and Xanthine Oxidase in Rats
Letters in Drug Design & Discovery Iron Involvement in Multiple Signaling Pathways of Atherosclerosis: A Revisited Hypothesis
Current Medicinal Chemistry Relaxin as a Cardiovascular Hormone: Physiology, Pathophysiology and Therapeutic Promises
Cardiovascular & Hematological Agents in Medicinal Chemistry A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Oxidative Stress, Preeclampsia and Cardiovascular Disease
Current Hypertension Reviews Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Gene Therapy in Cerebrovascular Diseases
Current Gene Therapy 20-Hydroxyeicosatetraenoic Acid is a Potential Therapeutic Target in Cardiovascular Diseases
Current Drug Metabolism